For decades, we've been told “Lower LDL is Better.” But what if, in our myopic obsession with LDL and ApoB, we’ve missed a ...

On August 31, 2020, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the presentation of data from ongoing Phase 1/2 clinical trials of ARO-APOC3 and ARO-ANG3 at the European Society of ...

Monthly olezarsen reduced triglycerides and apolipoprotein B in patients with hypertriglyceridemia but may have no impact on ...

Please provide your email address to receive an email when new articles are posted on . Plozasiran demonstrated durable improvement in triglycerides, APOC3 and other lipid parameters for patients with ...

BUFFALO, NY-March 20, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 5, entitled, ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has two late-stage cardiometabolic programs, ARO-APOC3 and ARO-ANG3. ARO-APOC3 is targeted to apolipoprotein C-III (APOC3), a component of very ...

Scientists have discovered several mutations in one gene that may safeguard a person from heart attacks. The mutations in this specific gene, known as APOC3, have been found to keep triglycerides at ...

The precise role of triglycerides in heart disease has been very difficult to determine. To help untangle the knotty problem two research groups studied large populations and identified rare ...

May 19, 2008 — Heavy, chronic use of marijuana causes increased levels of apolipoprotein C3 (apoC3), which in turn results in a major increase in triglyceride ...

Nanomedicine prompts RNA to make protein-based drugs to treat diseases. Now we can fine-tune protein production by dialling ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for ...